GSK to buy asthma drug developer for up to $1.4 billion in pipeline push
Bristol Myers Reaffirms Long-Term Financial Targets
Health Care Roundup: Market Talk
Bristol Myers Squibb Stock Opens Lower After Downgrade
Stock Market News
Here are the 20 worst-performing stocks among the S&P 500 in 2023
Biotech Stocks Were Tanking. The Cure? M&A.
Here are the 20 worst-performing stocks among the S&P 500 in 2023
Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review
Fusion Pharma climbs as radiopharmaceutical company flagged as potential merger target
Can Obesity Firms Continue Their Outperformance in 2024?
Healthcare Stocks Had a Terrible 2023. Things Are Looking Up.
Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%
Health Care Up as Deal Activity Continues -- Health Care Roundup
RayzeBio, Gracell, NIO, Intel, Manchester United, Arm, FedEx, and More Stock Market Movers
Biotech M&A Is Back—and So Are Biotech Stocks
RayzeBio Takes Short Trip From IPO to Buyout
Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion
Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion
Rethinking Immunotherapy for Cancer: When Is the Best Time to Stop?
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.